Source comparison
BPC-157 Research Pediatric Considerations: Comparison
Growth Plate Effects Not applicable (closed epiphyses in adults) Zero studies examining growth plate closure timing or cartilage differentiation VEGF upregulation could trigger premature fusion, limiting final height CNS Development Rodent studies show dopamin
This comparison does not assign a generated winner or score.
- Growth Plate Effects
- Not applicable (closed epiphyses in adults)
- Zero studies examining growth plate closure timing or cartilage differentiation
- VEGF upregulation could trigger premature fusion, limiting final height
- CNS Development
- Rodent studies show dopamine D2 modulation; no human CNS imaging data
- No data on myelination, synaptic pruning, or prefrontal cortex development
- Unknown effects on neurotransmitter system maturation through age 25
- Dosing & Pharmacokinetics
- Rat doses range 10 mcg/kg–10 mg/kg; human equivalent dose undefined
- No allometric scaling validated for pediatric metabolism or tissue distribution
- Weight-based scaling ignores developmental pharmacokinetic differences
- Regulatory Status
- No FDA-approved indication; available only as research compound
- Institutional review boards categorically prohibit pediatric trials without adult Phase 1 data
- Legal liability for off-label pediatric use falls entirely on prescriber
- Long-Term Safety
- No human studies beyond 8-week administration windows
- No tracking of growth velocity, bone age progression, or endocrine function post-use
- Developmental disruptions may not manifest until years after exposure